Tonight’s quick heads up…
Â
A quiet oncology story just posted a number that makes people stop skimming:
Â
92% complete response. 🧬
Â
BUT before we get deeper into that, a quick congrats to the SMS crew! đź‘€
Â
You saw why timing matters: we dropped a last-minute momentum alert today
around $2.00, and it tagged a high shortly after at $2.37.
Â
That’s the edge with text alerts… speed. ⏰
Â
When something starts moving and the window is tight, we don’t wait for email. The fastest heads-up often goes out by SMS first.
Â
Now back to that 92% complete response. 🧬
Â
But the part that changes the “interesting” into
“urgent to understand” is what happened next:
Â
✅ The FDA aligned on two registrational Phase 3 paths (H1 2026 kickoff)
⏱️ In-office delivery in under 10 minutes (no hours-long clinic marathons)
📌 Durability signal: 9-month CR held in 17/20 evaluable patients (85%)
✅ Fresh financing extends runway into 2028, so the plan can actually be
executed
Â
This is one of those setups where the narrative can flip fast — from “under-followed” to “why is everyone suddenly talking about this?”
Â
Full story drops tomorrow at 9:30AM EST.
You’ll want the details before the crowd shows up. 👀
Â
To your success,
Â
Max Masters
Co-founder, Market Tips Newsletter
Â